{'output': [['Elite Pharmaceuticals, Inc.', 'COMP', 'Announce', 'Received FDA approval for Phendimetrazine Tartrate Tablets USP, 35 mg.', 'EVENT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Operate_In', 'Specialty Pharmaceutical Company', 'ORG'], ['Phendimetrazine Tartrate Tablets USP, 35 mg.', 'PRODUCT', 'Relate_To', 'Generic Competitors', 'COMP'], ['Phendimetrazine Tartrate Tablets USP, 35 mg.', 'PRODUCT', 'Has', 'Retail Sales Approximately $4.5 Million', 'ECON_INDICATOR'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Considering', 'Strategic Options', 'CONCEPT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Owns', 'Nine Commercial Products', 'PRODUCT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Provides', 'Contract Manufacturing', 'SERVICE'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Operate_In', 'Northvale, NJ', 'GPE'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Pipeline of Proprietary Pharmacological Abuse Deterrent Opioid Products', 'PRODUCT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Niche Generic Products', 'PRODUCT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Lead Pipeline Products', 'PRODUCT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Once-Daily Opioid', 'PRODUCT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Sustained Release Oral Formulations of Opioids', 'PRODUCT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Patented Proprietary Technology', 'CONCEPT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Facility for Research, Development, and Manufacturing', 'FACILITY'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Products Under Review Pending Approval by the FDA', 'EVENT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Approved Products Pending Manufacturing Site Transfer', 'EVENT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'NDA Filing for SequestOx™', 'EVENT'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Licensed Products to TAGI Pharma, Epic Pharma, Dr. Reddy’s Laboratories and Valeant Pharmaceuticals International', 'COMP'], ['Elite Pharmaceuticals, Inc.', 'COMP', 'Has', 'Forward-Looking Statements', 'CONCEPT']]}